The tripeptide (methionine – lysine – proline) isolated from casein degradation has been shown to be an ACE inhibitor and lower systolic blood pressure in man. This development follows up on lactotripeptide present in Calpis products since 2012, and other peptide-based developments.

Nikkei Biotech news release, December 7, 2018